Importantly, restoring low [Cl−]i levels and therefore inhibitory actions of GABA by either an NKCC1 antagonist or a KCC2 enhancer attenuates the severity of many brain disorders [42,43,44]. Here, SLC12A5 is linked to brain disorder.